Download PDF
Semin Thromb Hemost 2006; 32(7): 709-715
DOI: 10.1055/s-2006-951455
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Thromboembolism in Women

Ida Martinelli1
  • 1A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical Specialties, Foundation IRCCS Policlinico, Mangiagalli and Regina Elena, University of Milan, Italy
Further Information

Publication History

Publication Date:
06 October 2006 (online)

    Permissions and Reprints

ABSTRACT

Venous thromboembolism (VTE) occurs in one of every 1000 individuals per year. The incidence is much lower in young persons. In persons younger than age 45, the incidence is one of every 10,000 individuals per year. VTE is a multifactorial disease due to the interaction of various risk factors that can be genetic (e.g., inherited thrombophilia), acquired (e.g., age, neoplastic or autoimmune diseases, antiphospholipid antibodies), or transient (e.g., surgical interventions, fractures, trauma, prolonged immobilization). VTE is found equally in the two sexes. There are other transient risk factors for VTE that are typical for females, and these render women more exposed than men to the risk of the disease during their lifetime. Such risk factors are encountered frequently in a woman's life; they are oral contraceptive (OC) use, hormone replacement therapy, and pregnancy/puerperium. Moreover, various obstetric complications have attributed at least in part to an impaired placental circulation, suggesting a thrombosis theory as their common basis. In this review, the relationship between VTE and risk factors specifically of women is discussed, also in relation to coagulation abnormalities causing inherited thrombophilia.

KEYWORDS

Venous thrombosis - thrombophilia - oral contraceptives - pregnancy - obstetrical complications

REFERENCES

  • 1 Martinelli I. Risk factors in venous thromboembolism.  Thromb Haemost. 2001;  86 395-403
    PubMedGoogle Scholar
  • 2 WHO Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception . Cardiovascular disease and steroid hormone contraception: Report of a WHO Scientific Group.  WHO Technical Report Series. 1998;  877 1-89
    PubMedGoogle Scholar
  • 3 Hannaford P. Health consequences of oral combined oral contraceptives.  Br Med Bull. 2000;  56 749-760
    PubMedGoogle Scholar
  • 4 Jordan W M. Pulmonary embolism.  Lancet. 1961;  1 1146-1147
    PubMedGoogle Scholar
  • 5 Sartwell P E, Masi A T, Arthes F G, Greene G R, Smith H E. Thromboembolism and oral contraceptives: an epidemiological case control study.  Am J Epidemiol. 1969;  90 365-380
    PubMedGoogle Scholar
  • 6 Vessey M P, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further case report.  BMJ. 1969;  2 651-657
    PubMedGoogle Scholar
  • 7 Royal College of General Practitioners' Oral Contraception Study . Oral contraceptives, venous thrombosis, and varicose veins.  J R Coll Gen Pract. 1978;  28 393-399
    PubMedGoogle Scholar
  • 8 Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study.  BMJ. 1986;  292 526
    CrossrefPubMedGoogle Scholar
  • 9 Gerstman B B, Piper T M, Tomita D K, Ferguson W J, Stadel B V, Lundin F E. Oral contraceptive estrogen dose and the risk of venous thromboembolic disease.  Am J Epidemiol. 1991;  133 32-37
    PubMedGoogle Scholar
  • 10 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Büller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third generation progestagen.  Lancet. 1995;  346 1593-1596
    CrossrefPubMedGoogle Scholar
  • 11 World Health Organization . Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.  Lancet. 1995;  346 1582-1588
    PubMedGoogle Scholar
  • 12 Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagens components.  Lancet. 1995;  346 1589-1593
    CrossrefPubMedGoogle Scholar
  • 13 Spitzer W O, Lewis M A, Heinemann L A, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disease: an international case-control study. The Transnational Research Group on Oral Contraceptives and the health of Young Women.  BMJ. 1996;  312 83-88
    PubMedGoogle Scholar
  • 14 Farmer R DT, Todd J C, Mac Rae K D, Williams T J, Lewis M A. Oral contraception was not associated with venous thromboembolic disease in recent study.  BMJ. 1998;  316 1090-1091
    PubMedGoogle Scholar
  • 15 Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci P M. Interaction between the G20210A mutation of prothrombin gene and oral contraceptive use in deep vein thrombosis.  Arterioscler Thromb Vasc Biol. 1999;  19 700-703
    CrossrefPubMedGoogle Scholar
  • 16 Bloemenkamp K WM, Rosendaal F R, Büller H R, Helmerhorst F M, Colly I P, Vandenbroucke J P. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias.  Arch Intern Med. 1999;  159 65-70
    CrossrefPubMedGoogle Scholar
  • 17 Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study.  Contraception. 1998;  57 291-301
    CrossrefPubMedGoogle Scholar
  • 18 Herings R MC, Urquhart J, Leufkens H GM. Venous thromboembolism among new users of different oral contraceptives.  Lancet. 1999;  354 127-128
    CrossrefPubMedGoogle Scholar
  • 19 Lewis M A, Heinemann L A, MacRae K D, Bruppacher R, Spitzer W O. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the health of Young Women.  Contraception. 1996;  54 5-13
    CrossrefPubMedGoogle Scholar
  • 20 Farley T M, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing risks.  Hum Reprod Update. 1999;  5 721-735
    CrossrefPubMedGoogle Scholar
  • 21 Vandenbroucke J P, Helmerhorst F M, Bloemenkamp K WM, Rosendaal F R. Third generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.  Am J Obstet Gynecol. 1997;  177 887-891
    PubMedGoogle Scholar
  • 22 Kemmeren J M, Algra A, Grobbee D E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.  BMJ. 2001;  323 131-134
    CrossrefPubMedGoogle Scholar
  • 23 Vasilakis C, Jick H, Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone.  Lancet. 1999;  354 1610-1611
    PubMedGoogle Scholar
  • 24 Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study.  Contraception. 2002;  65 187-196
    CrossrefPubMedGoogle Scholar
  • 25 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F, Vandenbroucke J P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects.  Arch Intern Med. 2000;  160 49-52
    CrossrefPubMedGoogle Scholar
  • 26 Pabinger I, Schneider B. GTH Study Group . Thrombotic risk of women with hereditary antithrombin III, protein C- and protein S-deficiency taking oral contraceptive medication.  Thromb Haemost. 1994;  71 548-552
    PubMedGoogle Scholar
  • 27 Martinelli I. Pros and cons of thrombophilia testing: pros.  J Thromb Haemost. 2003;  1 410-411
    CrossrefPubMedGoogle Scholar
  • 28 Stadel B V. Oral contraceptives and cardiovascular disease.  N Engl J Med. 1981;  305 612-618
    PubMedGoogle Scholar
  • 29 Rosendaal F R, van Hylckama-Vlieg A, Tanis B C, Helmerhorst F M. Estrogens, progestogens and thrombosis.  J Thromb Haemost. 2003;  1 1371-1380
    CrossrefPubMedGoogle Scholar
  • 30 Daly E, Vessey M P, Hawkins M M, Carson J L, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy.  Lancet. 1996;  348 977-980
    CrossrefPubMedGoogle Scholar
  • 31 Jick H, Derby L E, Myers M W, Vasilakis C, Newton K M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.  Lancet. 1996;  348 981-983
    CrossrefPubMedGoogle Scholar
  • 32 Grodstein F, Stampfer M J, Goldhaber S Z et al.. Prospective study of exogenous hormones and risk of pulmonary embolism in women.  Lancet. 1996;  348 983-987
    CrossrefPubMedGoogle Scholar
  • 33 Lowe G DO. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease.  J Intern Med. 2004;  256 361-374
    CrossrefPubMedGoogle Scholar
  • 34 Miller J, Chan B K, Nelson H D. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force.  Ann Intern Med. 2002;  136 680-690
    PubMedGoogle Scholar
  • 35 Quinn D A, Thompson B T, Terrin M L et al.. A prospective investigation of pulmonary embolism in women and men.  JAMA. 1992;  268 1689-1696
    CrossrefPubMedGoogle Scholar
  • 36 Herrington D M, Vittinghoff E, Howard R D et al.. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.  Arterioscler Thromb Vasc Biol. 2002;  22 1012-1017
    CrossrefPubMedGoogle Scholar
  • 37 UK Committee on Safety of Medicines and Medicines and Healthcare products Regulatory Agency . HRT: update on the risk of breast cancer and long-term safety.  Curr Probl Pharmacovigilance. 2003;  29 1-3
    PubMedGoogle Scholar
  • 38 Burns M M. Emerging concepts in the diagnosis and management of venous thromboembolism during pregnancy.  J Thromb Thrombolysis. 2000;  10 59-68
    PubMedGoogle Scholar
  • 39 Hibbard B M, Anderson M M, Drife J O. Report on confidential enquiries into maternal deaths in the United Kingdom 1991-93. London; Her Majesty's Stationery Office 1996
    Google Scholar
  • 40 Greer I A. Thrombosis in pregnancy: maternal and fetal issues.  Lancet. 1999;  353 1258-1265
    CrossrefPubMedGoogle Scholar
  • 41 Royal College of Obstetricians and Gynaecologists. Report of the RCOG Working Party on Prophylaxis against Thromboembolism in Gynaecology and Obstetrics. London; RCOG 1995
    Google Scholar
  • 42 Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci P M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium.  Thromb Haemost. 2002;  87 791-795
    PubMedGoogle Scholar
  • 43 Macklon N S, Greer I A. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience.  Scott Med J. 1996;  41 83-86
    PubMedGoogle Scholar
  • 44 Ray J G, Chan W S. Deep vein thrombosis during pregnancy and the puerperium: a metanalysis of the period of risk and the leg of presentation.  Obstet Gynecol Surv. 1999;  54 265-271
    CrossrefPubMedGoogle Scholar
  • 45 Drill V A, Calhoun D W. Oral contraceptives and thromboembolic disease.  JAMA. 1968;  206 77-84
    CrossrefPubMedGoogle Scholar
  • 46 Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy.  Acta Obstet Gynecol Scand. 1983;  62 239-243
    PubMedGoogle Scholar
  • 47 Letzky E, de Swiet M. Thromboembolism in pregnancy and its management.  Br J Haematol. 1984;  57 543-552
    PubMedGoogle Scholar
  • 48 Aaro L A, Juergens J L. Thrombophlebitis associated with pregnancy.  Am J Obstet Gynecol. 1971;  109 1128-1136
    PubMedGoogle Scholar
  • 49 Lindqvist P, Dahlbäck B, MarŜál K. Thrombotic risk during pregnancy: a population study.  Obstet Gynecol. 1999;  94 595-599
    CrossrefPubMedGoogle Scholar
  • 50 McColl M, Ramsay J E, Tait R C et al.. Risk factors for pregnancy associated venous thromboembolism.  Thromb Haemost. 1997;  78 1183-1188
    PubMedGoogle Scholar
  • 51 Barbour L A. Current concepts of anticoagulation therapy in pregnancy.  Obstet Gynecol Clin North Am. 1997;  24 499-521
    CrossrefPubMedGoogle Scholar
  • 52 Brill-Edwards P, Ginsberg J S, Gent M et al.. Safety of withholding heparin in pregnant women with a history of venous thromboembolism.  N Engl J Med. 2000;  343 1439-1444
    CrossrefPubMedGoogle Scholar
  • 53 Gerhardt A, Scarf R E, Beckmann M W et al.. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  N Engl J Med. 2000;  342 374-380
    CrossrefPubMedGoogle Scholar
  • 54 Simioni P, Sanson B J, Prandoni P et al.. Incidence of venous thromboembolism in families with inherited thrombophilia.  Thromb Haemost. 1999;  81 198-202
    PubMedGoogle Scholar
  • 55 Grandone E, Margaglione M, Colaizzo D et al.. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations.  Am J Obstet Gynecol. 1998;  179 1324-1328
    CrossrefPubMedGoogle Scholar
  • 56 Pabinger I, Nemes L, Rintelen C et al.. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden.  Hematol J. 2000;  1 37-41
    CrossrefPubMedGoogle Scholar
  • 57 Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci P M. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.  Thromb Haemost. 2001;  86 800-803
    PubMedGoogle Scholar
  • 58 Middeldorp S, Libourel E J, Hamulyák K, van der Meer J, Büller H. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden.  Br J Haematol. 2001;  113 553-555
    CrossrefPubMedGoogle Scholar
  • 59 Friederich P, Sanson B, Simioni P et al.. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis.  Ann Intern Med. 1996;  125 955-960
    CrossrefPubMedGoogle Scholar
  • 60 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft für Thrombose- und Hämostaseforschung (GTH) Study Group on Natural Inhibitors.  Arterioscler Thromb Vasc Biol. 1996;  16 742-748
    CrossrefPubMedGoogle Scholar
  • 61 Hough R, Makris M, Preston F. Pregnancy in women with thrombophilia: incidence of thrombosis and pregnancy outcome.  Br J Haematol. 1996;  93(suppl 2) 136
    PubMedGoogle Scholar
  • 62 Stirrat G M. Recurrent miscarriage. I. Definition and epidemiology.  Lancet. 1990;  336 673-675
    CrossrefPubMedGoogle Scholar
  • 63 Lindqvist P G, Merlo J. Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence?.  J Thromb Haemost. 2005;  3 221-223
    CrossrefPubMedGoogle Scholar
  • 64 Sibai B, Dekker G, Kupferminc M. Pre-eclampsia.  Lancet. 2005;  365 785-799
    CrossrefPubMedGoogle Scholar
  • 65 Göpel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth.  Lancet. 1999;  353 1411-1412
    CrossrefPubMedGoogle Scholar
  • 66 Grandone E, Margaglione M, Colaizzo D et al.. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with and without proteinuria.  Thromb Haemost. 1999;  81 349-352
    PubMedGoogle Scholar
  • 67 Facchinetti F, Marozio L, Grandone E, Pizzi C, Volpe A, Benedetto C. Thrombophilic mutations are a main risk factor for placental abruption.  Haematologica. 2003;  88 785-788
    PubMedGoogle Scholar
  • 68 Regan L, Rai R. Thrombophilia and pregnancy loss.  J Reprod Immunol. 2002;  55 163-180
    PubMedGoogle Scholar
  • 69 Vossen C, Preston F E, Conard J et al.. Hereditary thrombophilia and fetal loss: a prospective follow-up study.  J Thromb Haemost. 2004;  2 592-596
    CrossrefPubMedGoogle Scholar

Ida MartinelliM.D. Ph.D. 

A. Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital Policlinico

Via Pace, 9, 20122 Milan, Italy

Email: martin@policlinico.mi.it